See you at the Annual Meeting of The American Society of Human Genetics!

31/10/2012

We hope to meet you at the upcoming Annual Meeting of The American Society of Human Genetics in San Francisco, California! During the 6th and the 10th of November, we are going to be there with many news and updates of our services; and we are happy to show you how it works in person.

Top 10 Next Generation Sequencing Resources Online

23/10/2012

For the past few months we have been sharing news and commentaries about Next Generation Sequencing (NGS) and related software solutions and potential clinical applications. Here are our picks for the best online resources dedicated to this field of genomics. Have me missed any? Let us know what you think, and enjoy.

Genetic Engineering and Biotechnology News: NGS (news site)
NGS Leaders (community)
Edge Bio (blog)
NGS Leaders (blog)
BiteSize Bio NGS (blog)
Kevin’s GATTACA World (blog)
SEQAnswers (forum)
Next-Gen Sequencing (blog)
NGS-Expert.com(blog)
And finally our own Omixon Facebook, Twitter channel and blog.

Interview with Omixon CEO, Attila Bérces

16/10/2012

I had a chance to have a quick interview with the CEO of Omixon, Attila Bérces.

Here are his answers:

How did the idea for Omixon Target originate?

I have always been interested in how more accurate scientific computation is carried out. This is what we have been pursuing in genomics since the start of Omixon. Targeted sequencing is the application of Next Generation Sequencing (NGS) where precision and accuracy really matter.

Where do you see Omixon now in the global market of NGS software?

We are a niche player that adds significant value to NGS by helping users to better analyze and visualize their data.

When do you think NGS could play a really major role in diagnostics in the clinical settings?

NGS is already playing a very important role in cancer diagnostics. Traditionally, cancer has been characterized by how it affects organs, now it is characterized by the molecular pathways affected by the somatic mutations in cancer cells.

What will the future look like?

Sequencing-based typing can provide more accurate and higher resolution results than any alternatives. However, Sanger sequencing has some inherent ambiguity, since the two alleles are sequenced concurrently. This makes the analysis difficult and the resolution of ambiguities becomes a complicated multi-day workflow. NGS does not have the ambiguity of Sanger since the two alleles are clonally amplified. I believe that a huge number of labs will simply skip the Sanger sequencing step and go directly from hybridization assays into NGS.

BioIT World Europe – Oct 2012

14/10/2012

Omixon exhibited at BioIT World Europe, Vienna. Many scientists came to our booth for discussions with our staff as well as demonstrations of Omixon Target.

Prior to the conference our CTO, Tim Hague, gave a short course “Considerations for Analyzing Next Generation Sequencing.” This was held at the conference site in the InterContinental Hotel Vienna.

Here are Tim’s presentations:

ASHI 2012 – San Juan, Puerto Rico

13/10/2012

Omixon presented its poster, “HLA Typing from Next Generation Sequencing data,” at the 38th Annual Meeting of American Society for Histocompatibility and Immunogenetics in San Juan, Puerto Rico.

CEO, Attila Bérces, PhD and VP of Sales and Marketing, Fred Eberlein, attended the conference.